Pertuzumab: A New Targeted Therapy for HER2‐Positive Metastatic Breast Cancer

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Pharmacotherapy

• Publication date

  2014-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/phar.1338PMID 23918291
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines

  2014cited by this paper
• Abstract P2-16-07: Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data

  2013cited by this paper
• Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

  2012influential reference
• Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).

  2012cited by this paper
• Abstract P5-18-26: Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC)

  2012cited by this paper
• Abstract S5-1: Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC)

  2012cited by this paper
• Abstract P5-18-20: Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer.

  2012cited by this paper
• Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.

  2012influential reference
• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

  2012influential reference
• Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

  2012cited by this paper
• Maximizing human epidermal growth factor receptor 2 inhibition: a new oncologic paradigm in the era of targeted therapy.

  2012cited by this paper
• Annual San Antonio Breast Cancer Symposium に参加して

  2011cited by this paper
• S5-6: Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA).

  2011cited by this paper
• Resistance to HER2-directed antibodies and tyrosine kinase inhibitors

  2011cited by this paper
• Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

  2010cited by this paper
• Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

  2010cited by this paper
• Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.

  2010cited by this paper
• Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.

  2010cited by this paper
• Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

  2010cited by this paper
• Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab.

  2009cited by this paper
• Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors

  2009cited by this paper
• A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody–Drug Conjugate, in HER2+ Metastatic Breast Cancer (MBC) Patients Previously Treated with Conventional Chemotherapy, Lapatinib and Trastuzumab.

  2009cited by this paper
• The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

  2009cited by this paper
• Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

  2009cited by this paper
• Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

  2008cited by this paper
• Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes

  2008cited by this paper
• Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.

  2008cited by this paper
• Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study

  2007cited by this paper
• Trastuzumab: triumphs and tribulations

  2007cited by this paper
• Trastuzumab--mechanism of action and use in clinical practice.

  2007cited by this paper
• Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

  2007cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2007cited by this paper
• Rationale for Fixed Dosing of Pertuzumab in Cancer Patients Based on Population Pharmacokinetic Analysis

  2006influential reference
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.

  2005cited by this paper
• Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.

  2005influential reference
• Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.

  2004cited by this paper
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

  2004cited by this paper
• The ErbB/HER receptor protein-tyrosine kinases and cancer.

  2004cited by this paper
• Targeted Therapy in Breast Cancer

  2004cited by this paper
• New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors

  2004cited by this paper
• New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists

  2004cited by this paper
• The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells

  2004cited by this paper
• Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

  2003cited by this paper
• Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

  2002cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

  2001cited by this paper
• Specificity within the EGF family/ErbB receptor family signaling network

  1998cited by this paper
• ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.

  1996cited by this paper
• A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

  1996cited by this paper

• Impact of Anti-HER2 Therapies on Overall Survival in Patients with HER2-Positive Metastatic Breast Cancer: Focusing on Intracranial Efficacy of Emerging Treatments

  2025cites this paper
• Real-world disproportionality analysis of cardiac failure associated with novel antineoplastic agents in breast cancer: a pharmacovigilance study

  2025cites this paper
• Mechanism of miRNAs and miRNA-mRNA Regulatory Networks in Modulating Drug Resistance in HER2-Positive Breast Cancer: An Integrative Bioinformatics Approach

  2024cites this paper
• miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review

  2023cites this paper
• Analysis of miRNAs: Biomarkers for HER2-Targeted Breast Cancer Therapy

  2023cites this paper
• Palmatine, a Bioactive Protoberberine Alkaloid Isolated from Berberis cretica, Inhibits the Growth of Human Estrogen Receptor-Positive Breast Cancer Cells and Acts Synergistically and Additively with Doxorubicin

  2021cites this paper
• Recombinant immunotoxins development for HER2-based targeted cancer therapies

  2021cites this paper
• RAPPPID: Towards Generalisable Protein Interaction Prediction with AWD-LSTM Twin Networks

  2021cites this paper
• DUAL HER2 BLOCKADE WITH TRASTUZUMAB AND PERTUZUMAB IN HER2-POSITIVE BREAST CANCER: SINGLE CENTER REAL WORLD DATA

  2020cites this paper
• Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm

  2019cites this paper
• Novel Agents and the Future Perspectives

  2019cites this paper
• A HER2 bispecific antibody can be efficiently expressed in Escherichia coli with potent cytotoxicity.

  2018cites this paper
• Is there a role for immunotherapy in HER2-positive breast cancer?

  2018cites this paper
• The Use of Dietary Supplements, Stimulants, Medications and Associated Factors among Paddle Tennis Players

  2018cites this paper
• Krankheiten der oralen Mukosa

  2018cites this paper
• The Evolution of Oncology Companion Diagnostics from Signal Transduction to Immuno-Oncology.

  2017cites this paper
• Cell‐specific biomarkers and targeted biopharmaceuticals for breast cancer treatment

  2016cites this paper
• Targeting Estrogen Receptor Negative Breast Cancer Cells Using Diarylthiourea Analogs of SHetA2

  2016cites this paper
• Targeted therapy for gastric cancer: Current status and future directions (Review).

  2016cites this paper
• Harnessing the immune system to improve cancer therapy.

  2016cites this paper
• Management of patients treated with pertuzumab in the Australian clinical practice setting

  2016cites this paper
• Consecutive salinomycin treatment reduces doxorubicin resistance of breast tumor cells by diminishing drug efflux pump expression and activity.

  2016cites this paper
• Synthesis of Quinazoline Analogues with Differential Activity for HER2‐overexpressing Breast Cancer Cells

  2015cites this paper
• Degradable Hyaluronic Acid/Protamine Sulfate Interpolyelectrolyte Complexes as miRNA‐Delivery Nanocapsules for Triple‐Negative Breast Cancer Therapy

  2015cites this paper
• HER-2/HER-3 dimerization and HER-3 point mutations in breast cancer

  2014cites this paper